An Update on Scientific Advances and Clinical Strategies in Alzheimer’s Disease: Conference Reporter from AD/PD™ 2017

The Alzheimer’s & Parkinson’s Diseases (AD/PD™) 13th International Conference was held in Vienna, Austria, March 29 to April 2, 2017. The conference attracts international medical and scientific professionals worldwide and is at the forefront of unraveling the mechanisms and improving the treatment of neurodegenerative diseases, including Alzheimer’s disease (AD). In this activity, 2 experts summarize the key learnings from this year’s conference focusing on AD.


This activity has been designed to meet the educational needs of health care professionals involved in the diagnosis, treatment, or management of patients with AD.


Upon completion of this activity, participants will be better able to do the following:

  1. Identify therapies in development for the treatment of AD
  2. Analyze advances in the use of biomarkers to diagnose AD and evaluate treatment efficacy


Jeffrey L. Cummings, MD, ScD
Camille and Larry Ruvo Chair for Brain Health
Cleveland Clinic Lou Ruvo Center for Brain Health
Las Vegas, Nevada

Dennis J. Selkoe, MD
Vincent and Stella Coates Professor of Neurologic Diseases
Harvard Medical School
Ann Romney Center for Neurologic Diseases
Department of Neurology
Brigham and Women’s Hospital
Boston, Massachusetts

Disclosure of Conflicts of Interest

It is the policy of the Elsevier Office of Continuing Medical Education that all faculty, instructors, and planners disclose any real or apparent conflicts of interest relating to the topics of this educational activity. 

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Name of Faculty or PresenterRelationship Identified With:

Jeffrey L. Cummings, MD, ScD

Consultant/Advisor: AbbVie Inc, ACADIA Pharmaceuticals Inc, Accera, Inc, Actinogen Medical, Adamas Pharmaceuticals, Inc, Alkahest, Inc, Alzheon, Inc, Anavex Life Sciences Corp , Astellas Pharma Inc, AstraZeneca, Avanir Pharmaceuticals, Inc, Axovant Sciences Ltd., Biogen, Biotie, Boehringer Ingelheim GmbH, Chase Pharmaceuticals Corporation, Eisai Co., Ltd., FORUM Pharmaceuticals Inc., GE Healthcare, Genentech, Inc, Grifols, Intra-Cellular Therapies, Inc., Ionis Pharmaceuticals, Inc., Iris Pharma, Eli Lilly and Company, Lundbeck LLC, Medavante Inc, Merck & Co., Inc, NEUROTROPE, Novartis AG, NUTRICIA, Otsuka America Pharmaceutical, Inc, Pfizer Inc, Probiodrug, QR Pharma, Inc, Resverlogix Corp., F. Hoffmann-La Roche Ltd, Servier, Sunovion Pharmaceuticals Inc., Suven Life Sciences Limited, Takeda Pharmaceutical Company Limited, Toyoma, Transition Therapeutics Inc, and United Neuroscience, Inc

Grant/Research Support: Avid Radiopharmaceuticals, Teva Pharmaceutical Industries Ltd., and Cogstate Ltd

Stock Ownership:  Adamas Pharmaceuticals, Inc, Medavante Inc, Neurokos, NeuroTrax, Prana Biotechnology Limited, and Sonexa Therapeutics

Royalties, Patents: Copyright ownership of the Neuropsychiatric Inventory (NPI)

Dennis J. Selkoe, MD

Consultant/Advisor: Prothera Biosciences

Stock Ownership:  Prothera Biosciences

Non-faculty: Lyerka Miller, PhD; Sandy Breslow; Alison Kemp; and Bernard M. Abrams, MD, hereby state that neither they nor their spouse/life partner have any financial relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Financial Support

This activity has been supported by an independent educational grant from Biogen.

Provider Information

Jointly provided by the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC.

CME Credit (Physicians)

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Elsevier Office of Continuing Medical Education and Miller Medical Communications, LLC. The Elsevier Office of Continuing Medical Education is accredited by the ACCME to provide continuing medical education for physicians.

The Elsevier Office of Continuing Medical Education designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.


For all CME inquiries or special needs, please contact

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The Elsevier Office of Continuing Medical Education, Miller Medical Communications, LLC., and Biogen do not recommend the use of any agent outside of the labeled indications.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Course summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Course opens: 
Course expires: 

Available Credit

  • 1.00 AMA PRA Category 1 Credit(s)™
  • 1.00 Non-physician
Please login or register to take this course.